Cyclic and acyclic defensins inhibit human immunodeficiency virus type-1 replication by different mechanisms.
Seidel
Aprille
A
Department of Molecular Biology and Biochemistry, School of Biological Sciences and Center for Virus Research, University of California Irvine, Irvine, California, United States of America.
Ye
Ying
Y
de Armas
Lesley R
LR
Soto
Maira
M
Yarosh
William
W
Marcsisin
Renee A
RA
Tran
Dat
D
Selsted
Michael E
ME
Camerini
David
D
D000818:Animals; D019380:Anti-HIV Agents / Q000494:pharmacology*; D002470:Cell Survival; D023082:Defensins / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D015497:HIV-1 / Q000378:metabolism*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008156:Luciferases / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D010456:Peptides, Cyclic / Q000378:metabolism; D019718:Receptors, CXCR4 / Q000378:metabolism; D014779:Virus Replication; D023084:alpha-Defensins / Q000378:metabolism; D023083:beta-Defensins / Q000378:metabolism
D019380:Anti-HIV Agents; C527276:CXCR4 protein, human; C429483:DEFA1A3 protein, human; C406407:DEFB1 protein, human; D023082:Defensins; D010456:Peptides, Cyclic; D019718:Receptors, CXCR4; D023084:alpha-Defensins; D023083:beta-Defensins; C406413:human neutrophil peptide 1; D008156:Luciferases